Forbes Medi-Tech Inc.
OTC Bulletin Board : FMTI

June 17, 2008 16:05 ET

Forbes Medi-Tech Achieves "Minimum Bid Price Requirement" for Continued Listing on the Nasdaq Stock Market

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 17, 2008) - Forbes Medi-Tech Inc. (TSX:FMI)(NASDAQ:FMTI) ("Forbes" or "Company") announced today that the Company has demonstrated compliance with Nasdaq's Minimum Bid Price Requirement, as evidenced by a closing bid price of $1.00 or more for a minimum of ten consecutive trading days. Accordingly, the Nasdaq Hearings Panel has determined that the Company's shares will continue to be listed on The Nasdaq Stock Market.

"We believe that our dual-listing on stock markets in both the U.S. and Canada is strategically important to Forbes, and we are pleased to announce our continued listing on The Nasdaq Capital Market," said Charles Butt, President and CEO of Forbes Medi-Tech Inc.

"Forbes continues to execute on its business strategy by re-focusing our attention on our revenue-generating nutraceutical business while continuing to seek favourable business development opportunities for our pharmaceutical assets," added Mr. Butt.

About Forbes Medi-Tech

Forbes' strategy and vision is to develop and market a portfolio of nutraceutical products, including functional foods and dietary supplements, for the benefit of all consumers. An increasingly active population, the pursuit of healthier lifestyles and the desire to live longer have given rise to a category of products known as nutraceuticals. This category includes functional foods, which are conventional foods containing ingredients that provide additional health or nutritional benefits leading to possible risk reduction of contracting chronic diseases. For more information about Forbes Medi-Tech, please visit

This News Release contains forward-looking statements and forward-looking information, within the meaning of applicable securities laws (collectively, "forward-looking statements"), regarding the Company's continued listing on Nasdaq and the Company's strategy and vision. Forward-looking statements can be identified by forward-looking terminology such as "continue", "seek", "opportunities", "strategy", "vision", "to develop", and similar expressions or variations thereon. Forward-looking statements are inherently uncertain, and actual results may differ materially from the forward-looking statements due to a variety of risks, uncertainties and other factors, including, without limitation, the volatility of the Company's share price and its need to maintain compliance with the Minimum Bid Price Requirement and all other minimum listing standards of Nasdaq and the TSX in order for its shares to remain listed; uncertainty whether the Company will obtain any business development opportunities on acceptable terms or at all; the Company's need for additional future capital, which is not assured; the Company's dependence on a few existing, and its need for additional, customers; risks inherent in new product development; competition; intellectual property, product liability and insurance risks; manufacturing risks and the Company's dependency on a single manufacturer for its supplies of Reducol™; exchange rate fluctuations; and changes in the Company's business strategy or plans. For a further discussion of these and other known risks and uncertainties affecting the Company and its business, please see our latest Annual Information Form / Form 20-F, and other documents filed by us with Canadian and U.S. securities regulatory authorities at and Forward-looking statements are based on the beliefs, assumptions, and expectations of the Company's management at the time they are made, and the Company does not assume any obligation, except as required by law, to update its forward-looking statements if those beliefs, assumptions, or expectations or other circumstances should change.

Contact Information